-
4B Technologies Raises RMB 100M in Pre-Series B Financing Round
•
China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development, reportedly raised upwards of RMB 100 million (USD 14.3 million) in a Pre-Series B financing round. Dachen Capital led the round, which included contributions from Huaxi Investment, FangSheng Capital, ZGC Co-Innovation Fund, and Tao Capital,…
-
Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share
•
China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong Stock Exchange, priced at HKD 21.4 (USD 2.75) per share. That amounts to an HKD 672 million (USD 86.4 million) take-home. Financial PerformanceGaush generated RMB 1.298 billion (USD 186 million) and RMB 578 million (USD…
-
Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling
•
Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the Liaoning Administration for Market Regulation. The China-based firm was investigated by the bureau in November 2019, when the company was suspected of monopoly selling of levocarnitine active ingredients from November 2018 to June 2019. Investigation…
-
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205) at the 64th American Society of Hematology (ASH) annual meeting. Global Multi-Center Phase I/II StudyA global multi-center Phase I/II study for golidocitinib in recurrent refractory peripheral T-cell lymphoma (r/r PTCL) included a total of 51…
-
HitGen and Nitrase Therapeutics Enter Research Agreement
•
China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis, and screening of DELs to discover compounds that bind to certain targets that are of interest to Nitrase. Under the terms…
-
Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences Co., Ltd, a gene sequencing and diagnostic equipment developer based in Beijing, have put pen to paper on an in-depth collaboration. The two will integrate respective technologies and capabilities to set up a joint laboratory…
-
Innoforce Partners with RNAimmune for mRNA Development and Production
•
Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off from Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257). The former will provide the latter with services including DNA plasmid preparation, research into mRNA IVT stock solution technology, development of lipid nanoparticle (LNP) encapsulation process,…
-
NMPA Approves COVID-19 Antigen Detection Reagents from Four Companies
•
The National Medical Products Administration (NMPA) announced the marketing approvals for COVID-19 antigen detection reagents by Bioda Diagnostics (Wuhan) Co., Ltd, Getein Biotech, Inc, Triplex International Biosciences (China) Co., Ltd, and Zhongshan Bio-Tech Co., Ltd. A total of 40 such products have now been approved in China to date. Product…
-
Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics
•
Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The pairing is aimed at boosting the application of inductively coupled plasma mass spectrometry (ICP-MS) technology in clinics in China, and will provide advanced clinical testing and diagnostic solutions. No financial details were disclosed. Biozon’s Testing…
-
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New Drug (IND) filing for its in-house developed selective ATR kinase inhibitor TCC1727 by the US FDA. ATR Kinase and TCC1727 MechanismATR, namely ataxia telangiectasia and Rad-3-related protein, is a family of protein serine/threonine kinases and…
-
Acotec Scientific and Boston Scientific Enter Acquisition and Collaboration Agreement
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) and US major Boston Scientific Corporation (NYSE: BSX) entered into a partial acquisition offer and collaboration agreement. According to the offer, Boston Scientific will acquire up to 203.7 million of Acotec’s shares at HKD 20 (USD 2.57) apiece, amounting to a 65% stake.…
-
Biogen’s Aducanumab Administered to Chinese Patient for First Time
•
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a Chinese patient for the first time via the Hainan branch of Ruijin Hospital. The hospital is part of the Boao Lecheng medical pilot zone in Hainan province. Aducanumab: FDA Approval and IndicationAducanumab, a beta amyloid…
-
Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos
•
Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use Authorization (EUA) in Laos for its in-house developed COVID-19 mRNA vaccine, used for people aged 18 and above to prevent COVID-19 pneumonia through active immunization. The product, the first home-grown COVID-19 mRNA vaccine approved in…
-
Medbanks Set for IPO on Hong Kong Stock Exchange
•
Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial public offering (IPO) of 9.92 million shares to the Hong Kong Stock Exchange (HKSE), priced at HKD 18.6 (USD 2.39) per share. The online health platform expects to take home HKD 184 million (USD 23.66…
-
Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of all subjects and their clinical observation, alongside the clinical study summary report of a Phase I clinical study for its Category 1 GST-HG171. The results showed that GST-HG171 had good safety, tolerability, and pharmacokinetics, which…
-
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
•
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at the San Antonio Breast Cancer Symposium 2022 annual meeting. KN046/Albumin Paclitaxel in Metastatic TNBCThe Phase II clinical trial is designed to evaluate the efficacy, safety, and tolerability of KN046 combined with albumin paclitaxel in the…
-
Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center
•
Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a cooperation memorandum of understanding (MoU) with Shanghai’s Class 3A Zhongshan Hospital, a major teaching hospital affiliated to China’s National Health Commission. The three entities will collaborate on clinical studies in cancer and other diseases, create…
-
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
•
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New Orleans, Louisiana, USA, saw the latest updates from a string of China-based biotechs. Those included CARsgen Therapeutics Holdings Ltd (HKG: 2171), Gracell Biotechnologies Inc (Nasdaq.GRCL), Innovent Biologics Inc., (HKG: 1801), Junshi Biosciences (HKG: 1877, SHA:…
-
Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System
•
Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School, with a focus on the development of a new organoid 3D printing system. The tie-up is designed to develop bioengineering-based technologies to enable high-throughput and standardized organoid applications in academic research and the pharmaceutical industry.…
-
Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore
•
China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to the schizophrenia drug Seroquel (quetiapine fumarate immediate-release tablets) and Seroquel sustained release tablets to DCH Auriga. No financials were disclosed. Acquisition and Licensing HistoryLuye acquired exclusive rights to Seroquel from AstraZeneca via a USD 546…
